Dihydromyricetin
5 benefits mapped to clinical evidence across supplements.
Dose per serving from products
85 products in our catalogue print how much Dihydromyricetin a serving holds.
Most common: 250 mg to 500 mg, 48% of 85 products.
| Dose per serving | Products |
|---|---|
| 25 mg or less | 5 |
| 25 mg to 50 mg | 0 |
| 50 mg to 100 mg | 9 |
| 100 mg to 250 mg | 13 |
| 250 mg to 500 mg | 41 |
| 500 mg to 1 g | 13 |
| over 1 g | 4 |
Benefit Evidence
Research sources
Blood sugar (2)
- Ampelopsis grossedentata supplementation effectively ameliorates the glycemic control in patients with type 2 diabetes mellitus
PubMed ID: 30089792
Strong match — randomized Ampelopsis trial (contains DHM) showed decreased fasting plasma glucose and glycated albumin in T2D over 1 month.
- Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial
PubMed ID: 26032587
Strong match — RCT in NAFLD showed statistically significant decreases in glucose and HOMA-IR versus placebo over 3 months.
Metabolism (2)
- Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial
PubMed ID: 26032587
Strong match — RCT showed decreases in glucose, LDL, and HOMA-IR indicating improved metabolic parameters in NAFLD.
- Ampelopsis grossedentata supplementation effectively ameliorates the glycemic control in patients with type 2 diabetes mellitus
PubMed ID: 30089792
Good match — randomized trial (Ampelopsis) showed reduced fasting glucose and glycated albumin in T2D, supporting metabolic effects.
Heart health (1)
- Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial
PubMed ID: 26032587
Reasonable match — significant LDL-cholesterol reduction in NAFLD patients supports cardiovascular risk factor improvement.
Inflammation (1)
- Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial
PubMed ID: 26032587
Moderate evidence — trial rating notes multiple metabolic and inflammatory biomarkers improved over 3 months.
Liver support (1)
- Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial
PubMed ID: 26032587
Strong match — RCT in NAFLD patients showing significant improvements in glucose, LDL and insulin resistance suggesting liver-related metabolic benefit.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Dihydromyricetin
Search all152 products whose verified label declares Dihydromyricetin — not every bottle that mentions it in a title.